Skip to main content

Table 1 Baseline and disease characteristics by dosing group

From: A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia

  Part A Part B Total (n = 33)
0.3 mg/kg (n = 4) 1 mg/kg (n = 3) 3 mg/kg (n = 7) 10 mg/kg (n = 5) 10 mg/kg without oral iron (cohort B1) (n = 7) 10 mg/kg with oral iron (cohort B2) (n = 7)
Age, years 64.5 (58–75) 76.7 (63–88) 62.1 (44–78) 63.2 (53–75) 66.3 (50–79) 62.7 (51–72) 64.9 (44–88)
Sex
 Men 2 (50) 2 (67) 3 (43) 2 (40) 3 (43) 1 (14) 13 (39)
 Women 2 (50) 1 (33) 4 (57) 3 (60) 4 (57) 6 (86) 20 (61)
Race
 White 4 (100) 3 (100) 5 (71) 3 (60) 5 (71) 5 (71) 25 (76)
 Black or African American 0 0 2 (29) 1 (20) 2 (29) 2 (29) 7 (21)
 Asian 0 0 0 1 (20) 0 0 1 (3)
ECOG performance status
 0 1 (25) 1 (33) 2 (29) 0 0 0 4 (12)
 1 3 (75) 2 (67) 3 (43) 5 (100) 7 (100) 6 (86) 26 (79)
 2 0 0 2 (29) 0 0 1 (14) 3 (9)
Prior cancer treatment
 Systemic chemotherapy 4 (100) 3 (100) 7 (100) 5 (100) 5 (71) 4 (57) 28 (85)
 Radiotherapy 1 (25) 1 (33) 2 (29) 3 (60) 2 (29) 5 (71) 14 (42)
 Surgery 3 (75) 1 (33) 2 (29) 2 (40) 1 (14) 2 (29) 11 (33)
Median no. of prior oncology treatments 9.5 4.0 6.0 5.0 2.0 1.5 4.5
Mean serum hepcidin (ng/mL) 24.9 (18.51) 12.2 (8.48) 36.4 (21.87) 51.1 (39.81) 45.4 (20.23) 39.7 (38.99) 37.6 (28.46)
Mean hemoglobin (g/dL) 9.1 (1.45) 8.9 (0.91) 8.5 (0.83) 9.8 (0.84) 9.4 (1.13) 9.5 (0.31) 9.2 (0.95)
Mean erythropoietin (mIU/mL) 141.3 (92.71) 42.0 (20.16) 103.2 (135.14) 94.4 (116.49) 70.0 (60.87) 46.1 (25.67) 81.8 (88.29)
Mean serum ferritin (μg/L) 779.0 (303.64) 237.2 (136.68) 667.1 (683.65) 263.7 (178.90) 714.6 (553.58) 289.0 (175.70) 510.3 (464.15)
Cancer type
 Multiple myeloma 1 (25) 0 2 (29) 3 (60) 3 (43) 3 (43) 14 (42)
 Breast cancer 0 0 0 1 (20) 3 (43) 0 4 (12)
 Othera 3 (75) 3 (100) 5 (71) 1 (20) 1 (14) 4 (57) 15 (46)
  1. Values shown are for the safety population (i.e., all patients who received at least one dose of LY2787106 [n = 33]). Data are mean (range) for age; median for number of prior oncology treatments; mean (SD) for serum hepcidin, hemoglobin, erythropoietin, and serum ferritin; and n (%) for all other parameters
  2. ECOG Eastern Cooperative Oncology Group
  3. a“Other” cancer types include Waldenstrom’s macroglobulinemia (2 patients), pancreatic adenocarcinoma (2 patients), rectal cancer (2 patients), renal cell carcinoma, metastatic prostate cancer, colon adenocarcinoma, unknown primary presumed ovarian adenocarcinoma, metastatic sarcomatoid carcinoma of the distal esophagus, non-small cell lung cancer, adenocarcinoma of lung, gastrointestinal stromal tumor, and adenocarcinoma of the liver